GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » EV-to-EBITDA

BLFS (BioLife Solutions) EV-to-EBITDA : 287.16 (As of Jun. 27, 2025)


View and export this data going back to 1989. Start your Free Trial

What is BioLife Solutions EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioLife Solutions's enterprise value is $959.98 Mil. BioLife Solutions's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $3.34 Mil. Therefore, BioLife Solutions's EV-to-EBITDA for today is 287.16.

The historical rank and industry rank for BioLife Solutions's EV-to-EBITDA or its related term are showing as below:

BLFS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2963.01   Med: -4.99   Max: 2091.35
Current: 287.16

During the past 13 years, the highest EV-to-EBITDA of BioLife Solutions was 2091.35. The lowest was -2963.01. And the median was -4.99.

BLFS's EV-to-EBITDA is ranked worse than
97.58% of 496 companies
in the Medical Devices & Instruments industry
Industry Median: 15.47 vs BLFS: 287.16

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-27), BioLife Solutions's stock price is $21.49. BioLife Solutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.240. Therefore, BioLife Solutions's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


BioLife Solutions EV-to-EBITDA Historical Data

The historical data trend for BioLife Solutions's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions EV-to-EBITDA Chart

BioLife Solutions Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,157.64 -85.22 131.24 -54.25 746.28

BioLife Solutions Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -90.81 -82.25 1,488.64 746.28 306.42

Competitive Comparison of BioLife Solutions's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, BioLife Solutions's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's EV-to-EBITDA falls into.


;
;

BioLife Solutions EV-to-EBITDA Calculation

BioLife Solutions's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=959.982/3.343
=287.16

BioLife Solutions's current Enterprise Value is $959.98 Mil.
BioLife Solutions's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLife Solutions  (NAS:BLFS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

BioLife Solutions's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=21.49/-0.240
=At Loss

BioLife Solutions's share price for today is $21.49.
BioLife Solutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


BioLife Solutions EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLife Solutions Business Description

Traded in Other Exchanges
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Executives
Sarah Aebersold officer: VP, Global Human Resources BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman officer: Chief Financial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Aby J. Mathew officer: Chief Tech. Officer & Sr. VP 3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard officer: Vice President, Marketing 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster officer: Vice President of Operations C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Amy Duross director 8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Greef Roderick De director
Garrie Richardson officer: Chief Revenue Officer 3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Geraint Phillips officer: SVP, Global Operations 3303 MONTE VILLA, #310, BOTHELL WA 98021
Michael Rice director, officer: President & CEO C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p. 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Marcus Schulz officer: Vice President, Global Sales 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick director 16719 NE 139TH PLACE, WOODINVILLE WA 98072
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami director SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023